Conclusion: Overall, our study demonstrates that IFN discontinuation represents a safe strategy in MPN patients who achieved CHR, and particularly in patients with a driver VAF lower than 10% at time of discontinuation. Importantly, relapsed patients did not develop IFN resistance. Our data contributes to set the frame for future clinical trials evaluating the possibility of IFN treatment holidays in good responding MPN patients.
Interferon-Alpha (IFN) Therapy Discontinuation ... - MPN Voice
Interferon-Alpha (IFN) Therapy Discontinuation is Feasible in MPN
Written by
Manouche
To view profiles and participate in discussions please or .
Read more about...
4 Replies
•
Hi there, thank you for this information. It is very interesting one and gives me a hope, since I am on INF Alpha for many years now. Wishing you well.
Thanks for sharing. I've been on Pegasys for 4 years. I'm very thankful.
Not what you're looking for?
You may also like...
“Interferon” with MPN hematopoietic stem cells
stem cell (HSC) subpopulations contribute to myeloproliferative neoplasm (MPN) pathogenesis, and...
Discovery of a signaling feedback circuit that defines interferon responses in MPN
essential for IFN-suppressive effects on primary malignant erythroid precursors from MPN patients,...
Interferon-Alpha Reduces Myelofibrosis Risk, Mortality Rate in Low- and High-Risk Polycythemia Vera
survival (MFS) of high-risk patients was similarly higher in patients treated with IFN, with a...
Interferon alpha
Interferon Alpha and sent me the leaflet guide from MPN voice. The side affects seem vast and in...